scholarly journals Botulinum Toxin Type A Reconstituited with Lidocaine: A Report of 356 Consecutive Cases

2015 ◽  
Vol 1 (1) ◽  
pp. 1-4
Author(s):  
Raffaele Rauso ◽  
◽  
Pierfrancesco Bove
Keyword(s):  
Botulinum Toxin ◽  
Minimally Invasive ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Muscle Paralysis ◽  
Immediate Feedback ◽  
Off Label

Background: The purpose of this paper is to evaluate the predictability of the off-label aesthetic use of botulinum toxin type A (BoNTA) reconstituted with lidocaine. Material and Methods: Three-hundred and fifty-six (356) BoNTA treatments were performed on 118 patients, between the January 2010 and the January 2013; BoNTA was reconstituited with lidocaine. Results: A few minute after the BoNTA injection the effect of muscle paralysis was seen in all the cases, this allowed the Author to provide an optimal symmetric result with no need of a touch up procedure at the control after a week. Maior complication were not registered. Conclusion: The results of this study shows how the reconstitution of BoNTA with lidocaine may avoid imperfect results after the injections; all components retain their function and immediate feedback on the extent of paralysis to be expected from the chemodenervation action of BoNTA let the physician to have an immediate control of the final result. Keywords: Botulinum toxin, Facial aesthetic, Minimally-invasive, Lidocaine.

CP-048 Analysis of the ambulatory use of botulinum toxin type a in a tertiary hospital: authorised and off-label indications

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A19.2-A20
Author(s):  
MA Fernandez de Palencia Espinosa ◽  
V Arocas Casañ ◽  
MJ Sánchez Garre ◽  
L Menéndez Naranjo ◽  
MM Galindo Rueda ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Tertiary Hospital ◽  
Off Label

scholarly journals «Off-label» use of botulinic toxin type A preparations in neurological practice

2018 ◽  
Vol 20 (2) ◽  
pp. 195-201
Author(s):  
L R Akhmadeeva ◽  
Kh P Derevyanko
Keyword(s):  
Botulinum Toxin ◽  
Therapeutic Option ◽  
Botulinum Toxin Type A ◽  
Case Series ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Off Label Use ◽  
Off Label ◽  
Positive Effects ◽  
Label Use

The modern view on the application of botulinum toxin type A for the off-label use in neurology and foreign experience analysis are presented. The «off-label» category referred to any prescription of a medication in case of using it for unregistered indications, with product instruction violation or in the presence of contraindications including age restrictions. The sources of information about medicines were the leaflets of manufacturers of medicines and the State Register of Medicines. It is well known that Botulinum toxin type A is a good therapeutic option for treating children with cerebral palsy. Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in medication-overuse headache patients beyond the first year of treatment. Botulinum toxin type A is effective in the management of sialorrhea. Botulinum toxin type A is a safe and effective treatment for primary axillary hyperhidrosis and produces high levels of patient satisfaction. Facing depression with botulinum toxin: positive effects on mood have been observed in subjects who underwent treatment of glabellar frown lines with botulinum toxin and, in an open case series, depression remitted or improved after such a treatment. Botox injection significantly improved foot dystonia, pain and lower limb functional outcomes in patients with Parkinson’s disease with deep brain stimulation. The paper describes the problems associated with the lack of clinical data about the possibility of using botulinum toxin type A in different conditions, emphasizes the need to organize clinical trials and educational programs for neurologists as well as more active implementation of protocols for the treatment of patients.

scholarly journals Botulinum Toxin (Type A) as a Minimally Invasive Treatment for Gengival Smile: Case Report

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Broilo Kethylin ◽  
Ramalho Juliana Alves da Silva ◽  
Pereira Priscilla Aparecida ◽  
Ramalho Karen Muller ◽  
Morimoto Susana
Keyword(s):  
Case Report ◽  
Botulinum Toxin ◽  
Minimally Invasive ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Minimally Invasive Treatment ◽  
Invasive Treatment

Minimally Invasive Application of Botulinum Toxin Type A in Nasal Hypersecretion

ORL ◽  
2001 ◽  
Vol 63 (6) ◽  
pp. 382-384 ◽  
Author(s):  
Saskia Rohrbach ◽  
Rainer Laskawi
Keyword(s):  
Botulinum Toxin ◽  
Minimally Invasive ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

scholarly journals Botulinum Toxin Type A Reconstituted with Lidocaine: A Report of 1000 Consecutive Cases

2021 ◽  
Vol 11 (10) ◽  
pp. 4491
Author(s):  
Pierfrancesco Bove ◽  
Vincenzo Santillo ◽  
Giuseppe Colella ◽  
Rita Vitagliano ◽  
Romolo Fragola ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Immediate Feedback ◽  
The Face ◽  
Increasing Demand ◽  
Almost All ◽  
Upper Third ◽  
Minimally Invasive Methods

(1) Background: There is an increasing demand for a reversal of the aging process and, nowadays, more patients are seeking minimally invasive methods instead of surgery to meet this goal. The purpose of this paper is to evaluate the predictability of the off-label aesthetic use of botulinum toxin type A (BoNTA) reconstituted with lidocaine. (2) Methods: One thousand treatments, between January 2010 and January 2020, with BoNTA reconstituted with lidocaine for the rejuvenation of the upper third of the face, were performed and retrospectively evaluated. (3) Results: A few seconds after the BoNTA injections, the effect of muscle paralysis was seen in all cases; this allowed providing an optimal symmetric result with no need for a touch-up procedure at the control after three weeks. A burning sensation during the injections was claimed by almost all patients. Major complications were not registered. No touch-up procedures were required. (4) Conclusions: The results of this study show how the reconstitution of BoNTA with lidocaine may avoid imperfect results after the injections; the immediate feedback on the extent of paralysis to be expected from the chemodenervation action of BoNTA allows the physician to have immediate control of the final result.

Sign in / Sign up

Export Citation Format

Share Document